Amendments to the Claims:

1. (currently amended) A hybrid ~~Hybrid~~ bacterial toxin subunit comprising an A1-part of Shiga-toxin or Shiga-like toxin fused to an A2-part of Escherichia coli heat-labile enterotoxin.

2. (currently amended) The hybrid ~~Hybrid~~ bacterial toxin subunit according to claim 1, ~~characterized in that~~ wherein the A1-part is the [[an]] A1-part of Stx2e.

3. (currently amended) A hybrid ~~Hybrid~~ bipartite bacterial toxin comprising five B-subunits of Escherichia coli heat-labile enterotoxin and the hybrid bacterial toxin subunit according to claim 1, [[or 2]] wherein the A1-part is optionally the A1-part of Stx2e.

4. (currently amended) A nucleic ~~Nucleic~~ acid molecule comprising a nucleotide sequence encoding [[a]] the hybrid bacterial toxin subunit according to claim 1, [[or 2]] wherein the A1-part is optionally the A1-part of Stx2e.

5. (currently amended) A DNA fragment comprising [[a]] the nucleic acid molecule according to claim 4.

6. (currently amended) A recombinant ~~Recombinant~~ DNA molecule comprising

(i) [[a]] the nucleic acid molecule according to claim 4 under the control of a functionally linked promoter, or

(ii) a DNA fragment comprising the nucleic acid molecule according to claim 4 [[5]], under the control of a functionally linked promoter.

7. (currently amended) A live ~~Live~~ recombinant carrier comprising

(i) [[a]] the nucleic acid molecule according to claim 4,

(ii) a DNA fragment comprising the nucleic acid molecule according to claim 4, [[5]] or

(iii) a recombinant DNA molecule comprising (i) or (ii) ~~according to claim 6~~.

8. (currently amended) A host ~~Host~~ cell comprising

(i) [[a]] the nucleic acid molecule according to claim 4,

(ii) a DNA fragment comprising the nucleic acid molecule according to claim 4 [[5]],

(iii) a recombinant DNA molecule comprising (i) or (ii) under the control of a functionally linked promoter, ~~according to claim 6~~ or

(iv) a live recombinant carrier comprising (i), (ii) or (iii) ~~according to claim 7~~.

9. (cancelled)

10. (currently amended) A vaccine ~~Vaccine~~ comprising [[a]] the hybrid bacterial toxin subunit according to claim 1 ~~or 2 or a hybrid bipartite bacterial toxin according to claim 3,~~ and a pharmaceutically acceptable carrier, wherein the A1-part is optionally the A1-part of Stx2e.

11. (currently amended) A vaccine ~~Vaccine~~ comprising [[a]] the nucleic acid molecule according to claim ~~4, a DNA fragment according to claim 5, or a recombinant DNA molecule according to claim 6~~ and a pharmaceutically acceptable carrier.

12. (currently amended) A vaccine ~~Vaccine~~ comprising [[a]] the live recombinant carrier according to claim 7 ~~or a host cell according to claim 8~~ and a pharmaceutically acceptable carrier.

13. (currently amended) A vaccine ~~Vaccine~~ comprising antibodies against [[a]] the hybrid bacterial toxin subunit according to claim 1 ~~or 2 or a hybrid bipartite bacterial toxin according to claim 3,~~ and a pharmaceutically acceptable carrier, wherein the A1-part is optionally the A1-part

of Stx2e.

14. (currently amended) The vaccine ~~Vaccine~~ according to claim 10 ~~any of claims 10-13~~, ~~characterized in that~~ wherein said vaccine further comprises an additional antigen derived from a virus or micro-organism pathogenic to humans or animals, an antibody against said antigen or genetic information encoding said antigen.

15. (currently amended) The vaccine ~~Vaccine~~ according to claim 14, ~~characterized in that~~ wherein said vaccine comprises a virus or micro-organism [[is]] selected from the group consisting of Pseudorabies virus, Porcine influenza virus, Porcine parvo virus, Transmissible gastro-enteritis virus, Rotavirus, *Brachyspira hyodysenteriae, Escherichia coli, Erysipelothrix rhusiopathiae, Bordetella bronchiseptica, Brachyspira hyodysenteriae, Shigella sp., Salmonella choleraesuis, Salmonella typhimurium, Salmonella enteritidis, Haemophilus parasuis, Pasteurella multocida, Streptococcus suis, Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, Staphylococcus hyicus* and *Clostridium perfringens*.

16. (currently amended) A method of combatting *Shigella or Escherichia coli* infection comprising administering an effective amount of ~~Use of~~

(i) [[a]] the hybrid bacterial toxin subunit according to claim 1 [[or 2]], or

(ii) a hybrid bipartite bacterial toxin comprising five B-subunits of Escherichia coli heat-labile enterotoxin and the hybrid bacterial toxin subunit according to claim 1 ~~according to claim 3~~,

wherein the A1-part is optionally the A1-part of Stx2e

~~a nucleic acid molecule according to claim 4,~~

~~a DNA fragment according to claim 5,~~

~~a recombinant DNA molecule according to claim 6,~~

~~a live recombinant carrier according to claim 7, or~~

~~a host cell according to claim 8 for the manufacture of a vaccine for combating *Shigella* or *Escherichia coli* infection~~.

17. (currently amended) A method ~~Method~~ for the preparation of a vaccine ~~according to claims 10-15~~, said method comprising the admixing of

the [[a]] hybrid bacterial toxin subunit according to claim 1 ~~or 2, a hybrid bipartite bacterial toxin according to claim 3, a nucleic acid molecule according to claim 4, a DNA fragment according to claim 5, a recombinant DNA molecule according to claim 6, a live recombinant carrier according to claim 7, a host cell according to claim 8, or antibodies against a toxin according to claim 1-3,~~ and

a pharmaceutically acceptable carrier, wherein the A1-part is optionally the A1-part of Stx2e.

18. (new) A vaccine comprising the hybrid bipartite bacterial toxin according to claim 3 and a pharmaceutically acceptable carrier, wherein the A1-part is optionally the A1-part of Stx2e.

19. (new) A vaccine comprising the DNA fragment according to claim 5 and a pharmaceutically acceptable carrier.

20. (new) A vaccine comprising the recombinant DNA molecule according to claim 6 and a pharmaceutically acceptable carrier.

21. (new) A vaccine comprising the host cell according to claim 8 and a pharmaceutically acceptable carrier.